secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emmaus Life Sciences, Inc. (EMMA)
CIK:        0000822370
Form:       8-K
Filed at:   2025-04-14T23:59:59+00:00
Accession:  0001213900-25-031624
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emmaus Life Sciences reports 2024 net revenue down 44% to $16.7M; net loss widens to $0.10/share
--------------------------------------------------------------------------------

- Net revenue $16.7M in 2024, down 44% from $29.6M in 2023 due to inventory shortage.
- Loss from operations of $1.9M vs income of $3.5M in 2023.
- Net loss $6.5M ($0.10 per share) vs net loss $3.7M ($0.07) in 2023.
- Cash at Dec. 31, 2024: $1.4M, down from $2.5M a year earlier.
- Management expects 2025 net revenues to reach or exceed 2024 levels.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/822370/000121390025031624/0001213900-25-031624-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/822370/000121390025031624/ea0237926-8k_emmaus.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-031624

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer